<DOC>
	<DOCNO>NCT00095914</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , paclitaxel ABI-007 , work different way stop tumor cell divide stop grow die . Combining paclitaxel ABI-007 may kill tumor cell . PURPOSE : Randomized phase I trial study effectiveness combine paclitaxel ABI-007 treating patient locally advance metastatic solid tumor .</brief_summary>
	<brief_title>Paclitaxel ABI-007 Treating Patients With Locally Advanced Metastatic Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine whether change formulation alters pharmacokinetic profile paclitaxel plasma patient incurable locally advanced metastatic solid tumor treat ABI-007 paclitaxel . Secondary - Correlate pharmacokinetic data regimen decrease neutrophil count nadir patient . - Determine intra- interindividual pharmacokinetic variability ABI-007 patient . - Determine protein bind paclitaxel via measurement α-1-acid glycoprotein serum albumin level patient treat regimen . OUTLINE : This randomize , pilot study . - Courses 1 2 : Patients randomize 1 2 treatment arm . - Arm I : Patients receive paclitaxel IV 3 hour day 1 ABI-007 IV 30 minute day 22 . - Arm II : Patients receive ABI-007 IV 30 minute day 1 paclitaxel IV 3 hour day 22 . - Courses 3 beyond : All patient receive ABI-007 IV 30 minute day 1 . Courses repeat every 21 day absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : A total 20 patient accrue study .</detailed_description>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm malignant solid tumor Considered incurable Locally advance metastatic disease Likely responsive taxanebased therapy Patients refractory prior paclitaxel ineligible No symptomatic untreated brain metastasis carcinomatous meningitis No patient unable remain free corticosteroid therapy &gt; 4 week due CNS disease No previously untreated locally advanced breast cancer No hematologic malignancy PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 Life expectancy At least 3 month Hematopoietic Granulocyte count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hepatic Bilirubin normal ALT AST ≤ 1.5 time upper limit normal Renal Creatinine normal OR Creatinine clearance ≥ 60 mL/min Cardiovascular LVEF ≥ 40 % No clinical sign symptom heart failure No symptomatic congestive heart failure No unstable angina pectoris Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 2 month study participation No history allergic reaction attribute compound similar chemical biologic composition paclitaxel ( e.g. , docetaxel , Cremophor^® EL [ CrEL ] , polysorbate 80 [ Tween 80 ] , CrELcontaining medication [ e.g. , cyclosporine ] ) No history seizure disorder require anticonvulsant therapy No active serious infection No psychiatric illness social situation would preclude study compliance No uncontrolled illness PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent immunotherapy No concurrent filgrastim ( GCSF ) course 1 2 Chemotherapy See Disease Characteristics At least 3 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) No concurrent chemotherapy Endocrine therapy See Disease Characteristics At least 2 week since prior hormonal therapy Concurrent luteinizing hormonereleasing hormone agonist prostate cancer allow Radiotherapy At least 3 week since prior radiotherapy No concurrent radiotherapy Surgery Not specify Other More 2 week since prior drug , herbal preparation , dietary supplement know influence CYP3A4 ( e.g. , phenytoin , rifampin , Hypericum perforatum [ St. John 's wort ] , garlic supplement , grapefruit juice ) and/or CYP2C8 No concurrent substance know likely interfere pharmacokinetics paclitaxel ( e.g. , verapamil cyclosporine ) No concurrent investigational agent No concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>